Author(s): Bellodi C, Lidonnici MR, Hamilton A
Imatinib mesylate (IM), a potent inhibitor of the BCR/ABL tyrosine kinase, has become standard first-line therapy for patients with chronic myeloid leukemia (CML), but the frequency of resistance increases in advancing stages of disease. Elimination of BCR/ABL-dependent intracellular signals triggers apoptosis, but it is unclear whether this activates additional cell survival and/or death pathways. We have shown here that IM induces autophagy in CML blast crisis cell lines, CML primary cells, and p210BCR/ABL-expressing myeloid precursor cells. IM-induced autophagy did not involve c-Abl or Bcl-2 activity but was associated with ER stress and was suppressed by depletion of intracellular Ca2+, suggesting it is mechanistically nonoverlapping with IM-induced apoptosis. We further demonstrated that suppression of autophagy using either pharmacological inhibitors or RNA interference of essential autophagy genes enhanced cell death induced by IM in cell lines and primary CML cells. Critically, the combination of a tyrosine kinase inhibitor (TKI), i.e., IM, nilotinib, or dasatinib, with inhibitors of autophagy resulted in near complete elimination of phenotypically and functionally defined CML stem cells. Together, these findings suggest that autophagy inhibitors may enhance the therapeutic effects of TKIs in the treatment of CML.
Referred From: https://www.ncbi.nlm.nih.gov/pubmed/19363292
Author(s): Qu X, Yu J, Bhagat G, Furuya N, Hibshoosh H, et al.
Author(s): Yue Z, Jin S, Yang C, Levine AJ, Heintz N
Author(s): Edinger AL, Thompson CB
Author(s): Liang XH, Jackson S, Seaman M, Brown K, Kempkes B, et al.
Author(s): Aita VM, Liang XH, Murty VV, Pincus DL, Yu W, et al.
Author(s): Shen Y, Li DD, Wang LL, Deng R, Zhu XF
Author(s): Miracco C, Cosci E, Oliveri G, Luzi P, Pacenti L, et al.
Author(s): Daniel F, Legrand A, Pessayre D, Borrega-Pires F, Mbida L, et al.
Author(s): Koneri K, Goi T, Hirono Y, Katayama K, Yamaguchi A
Author(s): Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA
Author(s): Mathew R, Karantza-Wadsworth V, White E
Author(s): Degenhardt K, Mathew R, Beaudoin B, Bray K, Anderson D, et al.
Author(s): Chen S, Rehman SK, Zhang W, Wen A, Yao L, et al.
Author(s): Moretti L, Attia A, Kim KW, Lu B
Author(s): Akar U, Ozpolat B, Mehta K, Fok J, Kondo Y, et al.
Author(s): Xue L, Fletcher GC, Tolkovsky AM
Author(s): Shimizu S, Kanaseki T, Mizushima N, Mizuta T, Arakawa-Kobayashi S, et al.
Author(s): Spindler SR1
Author(s): Bergamini E,Cavallini G, Donati A, Gori Z
Author(s): Hanahan D, Weinberg RA
Author(s): Kumar S, Guru SK, Pathania AS, Kumar A, Bhushan S, et al.
Author(s): Bardeesy N, DePinho RA
Author(s): Devarajan E, Sahin AA, Chen JS, Krishnamurthy RR, Aggarwal N, et al.
Author(s): Devarajan E, Chen J, Multani AS, Pathak S, Sahin AA, et al.
Author(s): Lomonaco SL, Finniss S, Xiang C, Decarvalho A, Umansky F, et al.
Author(s): Zhuang W, Qin Z, Liang Z
Author(s): Dalby KN, Tekedereli I, Lopez-Berestein G, Ozpolat B
Author(s): Verma A, Wang H, Manavathi B, Fok JY, Mann AP, et al.
Author(s): Akar U, Chaves-Reyez A, Barria M, Tari A, Sanguino A, et al.